Ping-An Zhang

Ping-An Zhang

Auto-generated profile, based on publicly available information

Ping-An Zhang

National Clinical Research Center for Respiratory Disease The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in World Allergy Organization Journal
Verified
Journal Article
Open access
PZPing-An Zhang
Ping-An Zhang
JWJie-Lin Wang
Jie-Lin Wang
SFShi-Yan Fu
Shi-Yan Fu
HLHua-Lian Luo
Hua-Lian Luo
RQRun-Dong Qin
Run-Dong Qin
JLJing Li
Jing Li
Emerging research indicates that bronchiectasis often coexists with a range of allergic illnesses. The pathogenesis of both conditions is highly complex, involving a variety of interconnected factors, such as immune responses, metabolic pathways, and gut microbiota. However, the precise causal relationship between bronchiectasis and allergy-related conditions remains poorly understood. We obtained published GWAS datasets for 5 allergic disorders (allergic asthma, allergic rhinitis, atopic conjunctivitis, atopic dermatitis, and chronic rhinosinusitis) and bronchiectasis, along with data on 731 immune cells, 91 inflammatory proteins, 1400 plasma metabolites, and 473 gut microbiotas. Using bi-directional two-sample Mendelian Randomization (TSMR), we explored causal relationships between allergic diseases and bronchiectasis and validated these findings in a replication cohort. We also applied Linkage Disequilibrium Score Regression (LDSC) to assess genetic correlations between the conditions. Additionally, the mediating effects of immune cells, inflammatory proteins, metabolites, and gut microbiota on the relationship between allergic disorders and bronchiectasis were assessed through two-step TSMR and multivariate MR analysis. Our study revealed that allergic asthma, allergic rhinitis, atopic conjunctivitis, and atopic dermatitis all increased the risk of developing bronchiectasis, with no causal relationship identified in the reverse direction. Additionally, positive genetic associations were observed between allergic asthma, allergic rhinitis, atopic dermatitis, and bronchiectasis, respectively. We identified a total of forty immune cells, 5 inflammatory proteins, ninety plasma metabolites, and nineteen gut microbiota species as causal factors contributing to bronchiectasis onset. In mediation analysis, we found that the metabolic ratio of Retinol (Vitamin A) to oleoyl-linoleoyl-glycerol (18:1 to 18:2) was a risk factor for allergic asthma developing bronchiectasis, while the level of CD14 on CD33dim HLA-DR + CD11b + cells was a risk factor for allergic rhinitis. Two specific metabolic ratios—the Aspartate to N-acetylglucosamine to N-acetylgalactosamine ratio and the Methionine to phosphate ratio—served as, respectively, risk and protective factors for atopic dermatitis-developing bronchiectasis. Our findings suggest that allergic asthma, allergic rhinitis, atopic conjunctivitis, and atopic dermatitis increase the risk of developing bronchiectasis, with no evidence of a reverse causal relationship. Specifically, 3 metabolic ratios were identified as mediators between allergic diseases and bronchiectasis. Further studies are needed to clarify the underlying mechanisms.

5 January 2026 in World Allergy Organization Journal
Verified
Journal Article
Open access
PZPingan Zhang
Pingan Zhang
RQRundong Qin
Rundong Qin
WZWeixi Zhang
Weixi Zhang
YYYungang Yang
Yungang Yang
HLHuabin Li
Huabin Li
JLJing Li
Jing Li
While allergen-specific immunotherapy (AIT) is recognized as an effective treatment, its efficacy varies widely. However, whether clinical response trajectories to AIT differ among individuals and influence its effectiveness has not been investigated. This study aimed to characterize real-world clinical response trajectories to three-year AIT (3y-AIT). We conducted a retrospective multicenter study across 53 centers to identify clinical response trajectories in patients with house dust mite allergic asthma and rhinitis undergoing three-year AIT. The efficacy of AIT was primarily assessed using the Visual Analog Scale (VAS) for allergic symptoms at 4 time points: baseline (before AIT), and at 1, 2, and 3 years of treatment. Clustering analysis based on VAS changes at these time points was used to define response trajectories. Initial analysis was performed using data from 52 centers (Alliance cohort), and validation was conducted using data from a separate center (Guangzhou cohort). In the Alliance cohort, 4 distinct clinical response trajectories were identified. Cluster 1 showed symptom worsening in the first year, with no improvement by year 3. Cluster 2 exhibited symptom deterioration in the second year, followed by significant recovery and a positive response by year 3. Clusters 3 and 4, characterized by higher and lower baseline symptom severity, respectively, demonstrated marked improvement after 3 years of AIT. In the Guangzhou cohort, a similar pattern of 4 response trajectories was observed: higher baseline symptom severity and family tobacco exposure were key features of Cluster 1 (p < 0.001), while Cluster 2 had the highest rate of respiratory infections (>1/year, p < 0.001). Despite these distinct trajectories, first-year effectiveness emerged as an ideal predictor of the 3-year AIT response, with an AUC of 0.75. This study identified 4 primary treatment response trajectories to 3-year AIT in daily clinical practice, highlighting the heterogeneous nature of AIT responses among individuals. Notably, first-year effectiveness appears to be an ideal predictor of the 3-year AIT outcome.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
PZPing-An Zhang
Ping-An Zhang
JWJie-Lin Wang
Jie-Lin Wang
SFShi-Yan Fu
Shi-Yan Fu
HLHua-Lian Luo
Hua-Lian Luo
NLNai-Jian Li
Nai-Jian Li
JLJing Li
Jing Li
Background: Allergic diseases, including allergic asthma (AA), allergic rhinitis (AR), atopic dermatitis (AD), and allergic conjunctivitis (AC), often coexist. However, the specific inflammatory mediators driving their shared mechanisms remain unclear. This study explored causal relationships and identified multiomic mediators among allergic diseases using Mendelian randomization (MR). Methods: Large‐scale GWAS datasets from FinnGen and UK Biobank were analyzed. Linkage disequilibrium score regression (LDSC) and MR–robust adjusted profile scoring (MR‐RAPS) assessed genetic correlations and causal links. Crucially, multivariable MR (MVMR) adjusted for classical type 2 inflammatory factors to isolate independent effects. A two‐step MR framework evaluated the mediating roles of immune cells, metabolites, gut microbiota, and serum proteins. Results: Six disease pairs (AA–AR, AA–AD, AR–AA, AR–AD, AD–AA, and AD–AR) showed robust causal relationships independent of type 2 inflammation markers. Mediation analyses identified key inflammatory mediators, including immune cell subsets (e.g., CD45 on granulocytes), plasma metabolites (e.g., pentose acid), gut microbiota (e.g., Bacteroides intestinalis ), and notably, serum proteins such as ABHD12 and SEZ6L2. Pathway analyses highlighted cytokine–cytokine receptor interactions and lipid metabolism. Conclusions: This study maps a comprehensive causal network of allergic multimorbidity. We identified novel serum proteins and metabolic mediators beyond the classical type 2 inflammation axis, offering potential therapeutic targets for disrupting the inflammatory crosstalk between allergic diseases.

13 August 2026 in Allergy Medicine
Verified
Journal Article
Open access
PZPing-An Zhang
Ping-An Zhang
LZLi-Ling Zeng
Li-Ling Zeng
JWJie-Lin Wang
Jie-Lin Wang
XPXuan-Yu Pan
Xuan-Yu Pan
YYYi-Tian Yang
Yi-Tian Yang
JLJing Li
Jing Li

19 June 2026 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
SMSomayeh Mahdinloo
Somayeh Mahdinloo
PZPing‐An Zhang
Ping‐An Zhang
QZQiuyu Zhang
Qiuyu Zhang
MDMulan Deng
Mulan Deng
TLTianfeng Lan
Tianfeng Lan
JOJiang Ouyang
Jiang Ouyang
Melanoma progression is sustained by profound metabolic rewiring and immune suppression within the tumor microenvironment, where adipocyte‐derived lipid droplets (LDs) serve as key metabolic regulators. Here, we exploit this intrinsic biology by engineering resveratrol‐loaded LDs (RSV‐LDs) as natural, lipophilic nanocarriers to drive intracellular delivery and immunometabolic reprogramming. To achieve precise and localized administration, RSV‐LDs were integrated into soluble microneedles, enabling efficient transdermal delivery while minimizing systemic exposure. This strategy markedly increased the M1/M2 macrophage ratio and promoted robust CD8 + T‐cell infiltration, reshaping the immunosuppressive tumor niche. To further potentiate the activity of these infiltrating CD8 + T‐cells, we incorporated ROS‐responsive anti‐PD1 nanoparticles (aPD1‐NPs) via a thioketal linker, enabling tumor‐specific antibody release within the oxidative tumor milieu. Notably, transcriptomic and single‐cell analyses revealed coordinated activation of innate immune and metabolic pathways following treatment, with TLR7/8‐expressing monocytes emerging as a central communication hub among T, NK, and B cell populations. Together, these findings demonstrate that the microneedle‐based RSV‐LD/aPD1 platform induces localized metabolic and immune reprogramming, reshaping the tumor microenvironment to enhance antitumor immunity.

1 March 2026 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PZPing-An Zhang
Ping-An Zhang
JWJie-Lin Wang
Jie-Lin Wang
RQRun-Dong Qin
Run-Dong Qin
XSXiao-Nan Song
Xiao-Nan Song
RMRen-Ke Mo
Ren-Ke Mo
JLJing Li
Jing Li
Atopic dermatitis (AD) involves complex metabolic–immune dysregulation, but the molecular links remain unclear. This study integrates a multilevel analytical framework to systematically investigate the metabolic–immune crosstalk in AD. Using linkage disequilibrium score regression and a two-step Mendelian randomization approach, we established genetic correlations and inferred causal relationships between plasma metabolites and inflammatory proteins, identifying 1-palmitoyl-2-arachidonoyl-GPC (PA-GPC) as a protective metabolite that exerts its effect primarily through downregulation of interleukin-18 receptor 1 (IL-18R1). Integration of single-cell transcriptomic data further revealed elevated IL-18R1 expression in T cells within the AD microenvironment and enabled stratification of T cells based on PA-GPC–associated metabolic activity, identifying 33 differentially expressed genes. Subsequent least absolute shrinkage and selection operator (LASSO) regression, combined with machine learning models and SHapley Additive exPlanations analysis, consistently prioritized CD9 as a key regulator. Functional validation showed that PA-GPC attenuates tumor necrosis factor-alpha (TNF-α)/interferon-gamma (IFN-γ)–induced inflammatory responses in human immortalized keratinocyte (HaCaT) cells and suppresses Th2 cytokine production in T cells. IL-18R1 knockdown reduced CD9 expression and Th2 cytokine production in T cells, whereas CD9 knockdown did not affect IL-18R1 expression, indicating that IL-18R1 acts upstream of CD9. Moreover, CD9 knockdown impaired T-cell viability, activation, and Th2 cytokine production. Collectively, these findings characterize metabolic–immune crosstalk in AD and identify a PA-GPC–IL-18R1–CD9 regulatory axis with potential therapeutic implications.